ADVANCED MICRO DEVICES INC

AMD

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Driehaus Capital Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$4.0M

1 fund

Feb 17, 2026

$19.2M

1 fund

+380% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 132,677Value: $19.2M

**Signal Note: AMD Position Initiation by Driehaus Capital** Driehaus' $19.2M AMD entry is notable given the firm's biotech-focused mandate, suggesting conviction in AMD's AI/datacenter exposure as a secular growth driver rather than a traditional biotech play. The timing aligns with accelerating demand for GPU compute in clinical trial analysis, drug discovery AI, and genomic sequencing—areas seeing material adoption across biotech companies, potentially creating downstream beneficiary dynamics for Driehaus' existing portfolio.

Eventide Asset ManagementNEW

More AMD Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AXON2 funds NVDA2 funds VEEV2 funds VCYT2 funds LBRT2 funds RMBS2 funds UNP2 funds LITE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Eventide AMD Position Initiation** Eventide's $4.0M AMD entry is notable given the firm's biotech-focused mandate, suggesting confidence in AMD's healthcare/AI infrastructure applications—likely tied to accelerating AI adoption in drug discovery, genomics analysis, and clinical trial data processing. This positioning may signal anticipated tailwinds in computational biotech infrastructure ahead of broader sector AI spending cycles, though AMD is not a pure-play biotech asset and warrants scrutiny relative to Eventide's core thesis.